RAS oncogenes: weaving a tumorigenic web
Open accessThe DOI matches its Crossref record; 243 of the 243 references it cites were found in a registry or an index.
Abstract
RAS proteins are essential components of signalling pathways that emanate from cell surface receptors. Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer. A wealth of biochemical and genetic studies indicates that RAS proteins control a complex molecular circuitry that consists of a wide array of interconnecting pathways. In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Obviously, the RAF-MEK-ERK pathway is not the only pathway controlled by KRAS, 18 which is supported by findings demonstrating enhanced efficacy of combining MEK inhibitors with phosphoinositide 3-kinase inhibitors in NSCLC models.19,20”
From K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways (2019) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [17]
In the citing paper
“PDEδ has a large hydrophobic pocket that can bind farnesyl proteins, especially the lipid portion of KRAS protein, thereby preventing the farnesyl modification of KRAS protein from binding to cell membrane and inhibiting tumor cell proliferation and growth.339,340”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [340]
In the citing paper
“The resulting RAS-mediated signaling cascades drive tumor initiation, maintenance and progression by deregulating key cellular processes, for instance by increasing proliferation and suppressing apoptosis, but also by rewiring cellular metabolism and promoting alterations in the tumor microenvironment3.”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [3]
In the citing paper
“By constitutively activating these pathways, the Ras oncoprotein confers growth, survival and metastatic advantages to the cancer cell (11).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–243 of 243
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Qin, H., Chen, W., Takahashi, M., Disis, M. L., Byrd, D. R., McCahill, L., Bertram, K. A., Fenton, R. G., Peace, D. J., & Cheever, M. A. (1995) · PubMed · Cited by 65
Soudja, S. M., Wehbe, M., Mas, A., Chasson, L., de Tenbossche, C. P., Huijbers, I. J., den Eynde, B. J. V., & Schmitt‐Verhulst, A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4354 · Cited by 64 · cited 1×
“Whether RAS-transformed cells influence the immune response through direct recruitment of immunosuppressive cells or in conjunction with the induction of an inflammatory response remains to be elucidate”
BackgroundCell-specific regulation of oncogene-responsive sequences of the c-fos promoter.
Gutman, A., Wasylyk, C., & Wasylyk, B. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5381 · Cited by 62
Fossum, B., Olsen, A. C., Thorsby, E., & Gaudernack, G. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01517348 · Cited by 61
White, F. C., Benehacene, A., Scheele, J. S., & Kamps, M. (1997) · Growth Factors · doi:10.3109/08977199709021520 · Cited by 59
Regulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts
Kole, H. K., Resnick, R. J., Van Doren, M., & Racker, E. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90084-v · Cited by 57
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Kubuschok, B., Neumann, F., Breit, R., Sester, M., Schormann, C., Wagner, C., Sester, U., Hartmann, F., Wagner, M., Remberger, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1672 · Cited by 57 · cited 1×
“Thus, although T cells specific for the mutated RAS antigens can be found in patients with melanoma, pancreatic and colon cancers, they are often anergic and so inactive towards the tumou”
BackgroundSeliger, B., Harders, C., Wollscheid, U., Staege, M. S., Reske-Kunz, A. B., & Huber, C. (1996) · PubMed · Cited by 57
Kfir, S., Ehrlich, M., Goldshmid-Shagal, A., Liu, X., Kloog, Y., & Henis, Y. I. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8239-8250.2005 · Cited by 54
Jung, F., Haendeler, J., Hoffmann, J., Reissner, A., Dernbach, E., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000024412.24491.ca · Cited by 53
Gupta, S., Plattner, R., Der, C. J., & Stanbridge, E. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9294-9306.2000 · Cited by 53
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
Fullwood, P., Marchini, S., Rader, J. S., Martinez, A., Macartney-Coxson, D. P., Broggini, M., Morelli, M. C., Barbanti‐Brodano, G., Maher, E. R., & Latif, F. (1999) · PubMed · Cited by 52
Control of oncogenesis and cancer therapy resistance
Perona, R., & Sánchez‐Pérez, I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601552 · Cited by 52
Daly, A. C., Vizán, P., & Hill, C. S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043877 · Cited by 47
Lee, E., Yim, S., Lee, S., & Park, H. (2002) · PubMed · Cited by 47
Zhao, J., & Buick, R. (1995) · PubMed · Cited by 46
Quinlan, M. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203026 · Cited by 46
Burmer, G. C., Rabinovitch, P. S., & Loeb, L. A. (1991) · Environmental Health Perspectives · doi:10.1289/ehp.919327 · Cited by 45 · cited 1×
“Haematopoietic and lymphoid tissue 0% (3,076) 5% (5,978) 10% (8,753) 35.”
Zhang, Y. P., Nemunaitis, J. J., Kj, S., & Tong, A. W. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301331 · Cited by 44
Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia
Koorstra, J.-B. M., Hong, S., Shi, C., Meeker, A. K., Ryu, J. K., Offerhaus, G. J. A., Goggins, M., Hruban, R. H., & Maitra, A. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.114 · Cited by 44
Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-Ras
Denko, N. C., Stringer, J. R., Wani, M. A., & Stambrook, P. J. (1995) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02255779 · Cited by 43 · cited 1×
“Conversely, in cells that are deficient in DNA damage checkpoints (through the loss of p53, for example) deregulated DNA replicative activity that is induced by oncogenic RAS results in the generation of chromosome aberrations such as dicentric chromosomes, acentric chromosomes and double-minute chromosomes, leading t…”
BackgroundActivated K-ras is involved in regulation of integrin expression in human colon carcinoma cells
Schramm, K., Krause, K., Bittroff‐Leben, A., Goldin-Lang, P., Thiel, E., & Kreuser, E.-D. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<155::aid-ijc1>3.0.co;2-j · Cited by 43
Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer
Gjertsen, M. K., & Gaudernack, G. (1998) · Vox Sanguinis · doi:10.1111/j.1423-0410.1998.tb05462.x · Cited by 41 · cited 1×
“Thyroid 3% (4,137) 2% (5,166) 8% (4,662) 11 0.”
Downregulation of PAR‐4, a pro‐apoptotic gene, in pancreatic tumors harboring K‐ras mutation
Ahmed, M. M., Sheldon, D. G., Fruitwala, M. A., Venkatasubbarao, K., Lee, E. Y., Gupta, S., Wood, C., Mohiuddin, M., & Strodel, W. E. (2007) · International Journal of Cancer · doi:10.1002/ijc.23019 · Cited by 40
Studies on the structure and mechanism of H-ras p21
Goody, R. S., Pai, E. F., Schlichting, I., Rensland, H., Scheidig, A. J., Franken, S., & Wittinghofer, A. (1992) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1992.0037 · Cited by 39
Lee, E., Yim, S., Lee, S.-K., & Park, H. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15067-9 · Cited by 39
Sa, G., & Stacey, D. W. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.032 · Cited by 38 · cited 1×
“This suppressive effect is mediated by multiple RAS effector pathways and is exerted at the transcriptional, translational and post-translational level”
BackgroundSchmidt, C. R., Gi, Y. J., Patel, T. A., Coffey, R. J., Beauchamp, R. D., & Pearson, A. S. (2005) · Surgery · doi:10.1016/j.surg.2005.06.007 · Cited by 37 · cited 1×
“Thus, the expression of oncogenic RAS reduces the levels of E-cadherin through the upregulation of the E-cadherin transcriptional repressors SNAIL (also known as SNAI1) and SLUG (also known as SNAI2), the stimulation of E-cadherin proteolytic degradation and the induction of E-cadherin promoter methylatio”
BackgroundGores, G. J., & Guicciardi, M. E. (2005) · CRC Press eBooks · doi:10.1201/9781420038156.ch2 · Cited by 37
Urich, M., Senften, M., Shaw, P. E., & Ballmer‐Hofer, K. (1997) · Oncogene · doi:10.1038/sj.onc.1200982 · Cited by 35
Induction of the Apoptosis Inhibitor ARC by Ras in Human Cancers
Wu, L. I., Nam, Y.-J., Kung, G., Crow, M. T., & Kitsis, R. N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.114892 · Cited by 34 · cited 1×
“, and the upregulation of the anti-apoptotic proteins BCL-2 and apoptosis repressor with caspase recruitment domain (ARC; also known as NOL3”
BackgroundPruitt, K., Pestell, R. G., & Der, C. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006682200 · Cited by 30 · cited 1×
“This suppressive effect is mediated by multiple RAS effector pathways and is exerted at the transcriptional, translational and post-translational level”
BackgroundMultiple Levels of MHC Class I Down‐Regulation by ras Oncogenes
Lohmann, S., Wollscheid, U., Huber, C., & Seliger, B. (1996) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.1996.d01-73.x · Cited by 30 · cited 1×
“First, oncogenic activation of RAS reduces the surface expression of antigen-presenting major histocompatibility complexes (MHC) on cancer cells, and such downregulation results in decreased immunogenicity of the RAS-transformed cell”
BackgroundRibozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line
Tokunaga, T., Tsuchida, T., Kijima, H., Okamoto, K., Oshika, Y., Sawa, N., Ohnishi, Y., Yamazaki, H., Miura, S., Ueyama, Y., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1363 · Cited by 30
High expression of ras p21 correlates with increased rate of abnormal mitosis in NIH3T3 cells.
Hagag, N. G., Diamond, L., Palermo, R. E., & Lyubsky, S. L. (1990) · PubMed · Cited by 29
Testa, J. E., Medcalf, R. L., Cajot, J., Schleuning, W. D., & Sordat, B. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430513 · Cited by 25 · cited 1×
“Oncogenic HRAS G12V -mediated upregulation of matrix metalloproteinase 2 (MMP2), MMP9 and urokinase-type plasminogen activator (uPA) has been shown to be instrumental in removing the physical confines of the basement membrane, with upregulation of uPA especially important in potentiating endothelial cell migration and…”
BackgroundTestorelli, C., Bussini, S., Filippi, R. D., Marelli, O., Orlando, L., Greiner, J. W., Grohmann, U., Tentori, L., Giuliani, A., Bonmassar, E., et al. (1997) · PubMed · Cited by 20
The Fibrinolytic System and Matrix Metalloproteinases in Angiogenesis and Tumor Progression
Engelse, M. A., Hanemaaijer, R., Koolwijk, P., & van Hinsbergh, V. W. M. (2004) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2004-822972 · Cited by 20
Expression ofRap 1 suppresses genomic instability ofH-ras transformed mouse fibroblasts
Wani, M. A., Denko, N. C., & Stambrook, P. J. (1997) · Somatic Cell and Molecular Genetics · doi:10.1007/bf02679971 · Cited by 16 · cited 1×
“Conversely, in cells that are deficient in DNA damage checkpoints (through the loss of p53, for example) deregulated DNA replicative activity that is induced by oncogenic RAS results in the generation of chromosome aberrations such as dicentric chromosomes, acentric chromosomes and double-minute chromosomes, leading t…”
BackgroundReduced stimulation of helper T cells by Ki-ras transformed cells.
Maudsley, D. J., Bateman, W. J., & Morris, A. G. (1991) · PubMed · Cited by 13
The effect of H-ras expression on tumorigenicity and immunogenicity of Balb/c 3T3 fibroblasts
Ehrlich, T., Wishniak, O., Isakov, N., Castel, O. C., Segal, S., Rager‐Zisman, B., & Gopas, J. (1993) · Immunology Letters · doi:10.1016/0165-2478(93)90156-v · Cited by 13 · cited 1×
“First, oncogenic activation of RAS reduces the surface expression of antigen-presenting major histocompatibility complexes (MHC) on cancer cells, and such downregulation results in decreased immunogenicity of the RAS-transformed cell”
BackgroundJanus faces of ras: anti or pro-apoptotic?
Arber, N. (1999) · APOPTOSIS · doi:10.1023/a:1009651406017 · Cited by 12
Chironna, M., Calabrò, M. L., Quarto, M., Germinario, C. A., Fiore, J. R., Favero, A., Potenza, D., Chieco‐Bianchi, L., & Barbuti, S. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960315)65:6<778::aid-ijc12>3.0.co;2-0 · Cited by 7
Cited by
Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
“The proteins encoded by these genes are extremely homologous, and they belong to the small guanosine triphosphate (GTP)-binding protein (G protein) superfamily [46].”
BackgroundTargeting Ferroptosis as a Vulnerability in Cancer
Lei, G., Zhuang, L., & Gan, B. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00459-0 · Cited by 2,252
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Metadata
- Authors
- Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D.
- Affiliations
- New York University (US)
- ORCID
- Grabocka, Elda
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-13
- Volume
- 11
- Issue
- 11
- Pages
- 761-774
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3632399
- OpenAlex
- W1970527559
- Cited by
- 1,789
- References
- 239
- Citations by year
- 2026: 78 · 2025: 95 · 2024: 108 · 2023: 109 · 2022: 123 · 2021: 154 · 2020: 113 · 2019: 144 · 2018: 124 · 2017: 143 · 2016: 156 · 2015: 139 · 2014: 123 · 2013: 111 · 2012: 59
- FWCI
- 8.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Cancer Research Institute
- National Cancer Institute (R01CA055360, 1F32CA13922, CA 055360, R37CA055360, R56CA055360)
- National Institute of General Medical Sciences (R01GM078266, GM078266)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, oncogenic Ras mutations, carcinogenesis, Ras isoforms, missense mutations, cell-autonomous effects, non-cell-autonomous effects, signaling pathways, cancer
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasm Metastasis, Genes, ras, Apoptosis, Mutation, Missense, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.